Abstract

Background: Brain metastases are common in patients with metastatic melanoma and median overall survival from their diagnosis is typically 17–22 weeks. We assessed dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain.Methods: We undertook a multicentre, open-label, phase 2 trial in 24 centres in six countries. We enrolled patients with histologically confirmed Val600Glu or Val600Lys BRAF-mutant melanoma and at least one asymptomatic brain metastasis Read More...

 

Melanoma Research Foundation

Donate Today

Every day the Melanoma Research Foundation works to make the fight against melanoma easier.
Your donation will help us support patients, fund research and advocate for the melanoma community.